Arcus Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In millions, except per share amounts)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| License and development services (Includes $5, $20, $23 and $192 from a related party) | $8 | $20 | $36 | $192 |
| Other collaboration(Includes $1, $6, $31 and $22 from a related party) | 1 | 6 | 31 | 22 |
| Total revenues | 9 | 26 | 67 | 214 |
| Operating expenses: | ||||
| Research and development (Includes $1, $13, $2 and $19 from a related party) | 117 | 141 | 352 | 402 |
| General and administrative(Includes $—, $3, $— and $5 from a related party) | 23 | 27 | 76 | 84 |
| Total operating expenses | 140 | 168 | 428 | 486 |
| Loss from operations | (131) | (142) | (361) | (272) |
| Non-operating income (expense): | ||||
| Interest and other income, net | 6 | 10 | 23 | 31 |
| Interest expense | (3) | (3) | (9) | (6) |
| Total non-operating income, net | 3 | 7 | 14 | 25 |
| Loss before income taxes | (128) | (135) | (347) | (247) |
| Income tax expense | — | — | — | — |
| Net loss | $(128) | $(135) | $(347) | $(247) |
| Net loss per share: | ||||
| Basic and diluted | $(1.00) | $(1.27) | $(2.74) | $(2.39) |
| Shares used to compute net loss per share: | ||||
| Basic and diluted | 127.4 | 106.5 | 126.3 | 103.7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.